Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 ...
Treatment options for pancreatic neuroendocrine tumors (PNETs) have expanded considerably based on data from pivotal trials such as RADIANT-3 (NCT00510068), 1 Study A6181111 (NCT0 ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide ...
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...
In addition to the some of the above studies being retrospective, the conflicting data between multiple studies seem to originate from two major issues, the first one being the stage of patients ...
Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...
Targeted Oral Therapies in Progressive Small Bowel Neuroendocrine Tumor: Everolimus and Cabozantinib
Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...
Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on everolimus armObjective response rate (ORR) was h ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results